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Abstract 
Resveratrol is a bioactive plant compound that has drawn scientist and media attention 
due to its protective effects against a wide variety of illnesses, including cardiovascular 
diseases and cancer. In the last two decades, a plethora of preclinical studies have 
shown these beneficial effects, and some of them have been supported by clinical trials. 
However, there are few epidemiological studies assessing these relationships, showing 
mostly inconsistent results between them. This could be partially due to difficulty of 
accurately estimating dietary resveratrol exposure. The development of Phenol-
Explorer, a database containing resveratrol food composition data, will facilitate the 
estimation of resveratrol intake. Moreover, the discovery and validation of a nutritional 
biomarker of this exposure, urinary resveratrol metabolite profile, will allow a more 
accurate assessment of dietary resveratrol exposure. Few epidemiological studies have 
assessed the potential health effects of resveratrol. Resveratrol was not associated with 
total mortality, cancer or cardiovascular events; but it was associated with the 
improvement of serum glucose and triglyceride levels, and the decrease of heart-rate. 
Together, these findings suggest a potential cardioprotective effect of resveratrol in 
epidemiological studies, although the evidence is still scarce. 
 
Introduction 
Resveratrol is the parent compound of the stilbene family of molecules, which include 
glycosides (piceid) and polymers (viniferins), found mainly in grape and grape 
products, such as red wine, and in very low amounts in peanuts, pistachios, some 
berries, beer, tomato skin, chocolate and apple.
1-5
 Interest in resveratrol in nutrition and 
medicine started in 1992 when it was proposed to explain some of the cardiovascular 
protective effects of red wine in the French Paradox.
6
 Since then, the scientific literature 
on resveratrol has exponentially increased,
7
 and thousands of studies, especially in in 
vitro and in animal models, have investigated its potential activities regarding the 
prevention or delay of cancer, cardiovascular and neurodegenerative diseases, and 
aging. Despite the intensive research, few clinical trials on humans have been performed 
to date. These preclinical and clinical studies have shown that resveratrol exerts several 
potential beneficial activities such as the improvement of inflammatory and oxidative 
stress markers, glucose metabolism, and endothelial function, inhibiting platelet 
aggregation, modulating signaling pathways (e.g., increasing Sirtuin 1 expression), 
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inducing apoptosis and inhibiting angiogenesis, metastasis, and tumor growth. A recent 
review extensively summarizes the findings from these investigations.
8
 
Experimental studies mostly use pharmaceutical doses of nutrients/compounds, whereas 
large epidemiological studies, whether observational or interventional, give insight into 
the effects of dietary doses. The main limitation of these studies is the inaccuracy in the 
assessment of nutrient/compound exposure leading to discrepancies in the final findings 
between studies. The main method to assess dietary exposure is dietary questionnaires 
and/or biomarkers.
9
 
The aim of the current article is to review the dietary assessment methodologies for 
measuring resveratrol exposure and critically evaluate their pros and cons. Furthermore, 
results of epidemiological studies on resveratrol and health effects obtained by dietary 
questionnaires or biomarkers are summarized and compared. 
 
Resveratrol and piceid exposure assessment through dietary questionnaires 
In nutritional studies, the traditional method to estimate dietary intake of certain 
nutrient/compound is through dietary questionnaires and a food composition table. 
Researchers are usually interested in long term exposure and therefore the surveys most 
commonly used are single food frequency questionnaires (FFQs), food propensity 
questionnaires, diet histories, multiple 24-h recalls and 3- or 7-day food records. 
The advantages of this approach are the relatively low cost, the ease and simplicity of 
completing the questionnaires and processing the data, and finally, the large amount of 
dietary data gathered together, including nutrients, foods and even dietary patterns. The 
main limitation of the questionnaires is that they are mostly self-reported, so they are 
based on memory of the subjects and their ability to estimate food portion sizes.
10
 
However, the use of new technologies is facilitating and improving the accuracy of the 
subjects‟ responses, such as „personal digital assistant-„, „mobile-phone-„, „interactive 
computer-„, „web-„, „camera- and tape recorder-„, and „scan and sensor-based‟ 
technologies.
11
 The second drawback is related to the limited food composition data 
available and the high variability of composition, particularly for micronutrients and 
phytochemicals, between similar foods, and even in the same type of food. 
Food composition data on resveratrol and piceid 
To the best of our knowledge, Phenol-Explorer is the only food composition database 
containing data on resveratrol and piceid so far. Phenol-Explorer (www.phenol-
explorer.eu) is an online comprehensive food composition database on all known 
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polyphenols. It contains data on 502 individual polyphenols from all classes 
(flavonoids, phenolic acids, lignans, and stilbenes) in 452 foods extracted from the 
scientific literature.
12
 Although limited food composition data on resveratrol is given in 
a few articles.
1, 2
 Resveratrol and piceid are present in high concentrations in grape and 
grape products, such as wines, and in lower concentrations in peanuts, pistachios, 
berries, beer, tomato, chocolate and apple (Table 1). It is worth bearing in mind that, 
concentrations of resveratrol and piceid highly varied in foods, particularly in wine, 
depending in agronomic and environmental factors, grape varieties, and wine-making 
technology (e.g. red wine vs. white wine).
13, 14
 
Estimation of dietary resveratrol and piceid intakes 
Only a few epidemiological studies have estimated the dietary intake of resveratrol and 
piceid so far using validated dietary questionnaires for polyphenol-rich foods, such as 
wine. The first one was the European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Spain cohort, including data on approximately 40,000 men and 
women aged 35-64 years and recruited in the 1990s from northern and southern regions 
of Spain.
1
 In this study, a validated diet history, covering 600 food items, and ad hoc 
food composition table were used. The database on cis- and trans-resveratrol and cis- 
and trans-piceid was based on a systematic literature search using data mainly from 
Spanish foods, analyzed using HPLC diode array or GC/MS and converted into mg/100 
g fresh weight. The estimated mean (SD) intake of resveratrol and piceid together was 
0.93 (1.67) mg/day and nearly 32% of the individuals were non-consumers. The most 
abundant of the four stilbenes studied was trans-piceid (53.6%), followed by trans-
resveratrol (20.9%), cis-piceid (19.3%) and cis-resveratrol (6.2%). The main food 
sources were wines (98.4%), grapes and grape juices (1.6%), whereas peanuts, 
pistachios and berries contributed less than 0.01%. The second study was the 
SUpplémentation en VItamines et Minéraux AntioXydants (SU.VI.MAX), a French 
cohort consisting of ~5,000 men and women aged 45-60 years who were recruited 
between 1995 and 1996.
15
 In order to estimate resveratrol and piceid intake, at least six 
24-h dietary recalls and the Phenol-Explorer database were used. The mean (SD) intake 
of resveratrol and piceid were 0.45 (0.45) and 0.94 (1.04) mg/d, respectively. Moreover, 
the mean (SD) intake of other stilbenes was estimated: piceatannol 3-O-glucoside 1.3 
(1.6) mg/d, d-viniferin 0.84 (1.02) mg/d, piceatannol 0.76 (0.93) mg/d, pallidol 0.27 
(0.33) mg/d, and e-viniferin 0.2 (0.25) mg/d. Food sources of stilbenes were not 
presented in the study. The third cohort was the PREvención con DIeta MEDiterránea 
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(PREDIMED) study.
16
 Around 7,000 men and women, aged 55-80 years and at high 
cardiovascular risk were enrolled from 2003 to 2009 in this large multicenter clinical 
trial in Spain. At baseline, a validated 137-item FFQ was collected and Phenol-Explorer 
was used to convert food consumption into resveratrol and piceid intake. Mean (SD) 
total stilbene intake was 1.84 (3.39) mg/d and the most abundant sources were red wine 
(94%), white wine (2%), and grapes (1%). The fourth study was the cohort of 304 
institutionalized elderly living in Asturias (Spain). In this cross-sectional study, a 372-
item FFQ and Phenol-Explorer database were used to estimate resveratrol and piceid 
intake. The mean (SD) daily consumption of stilbenes was 3.06 (5.56) and 0.62 (1.33) 
mg/d for men and women, respectively, and red wine was the richest source (99.3%).
17
 
The fifth study was the Polish arm of the HAPIEE cohort (Health, Alcohol and 
Psychosocial factors in Eastern Europe). A total of 10,477 men and women, aged 45-69 
years, completed a validated 148-item FFQ. In this study, food composition data on 
stilbenes were also obtained from the Phenol-Explorer database. The mean (SD) 
stilbenes intake was 0.2 (0.6) mg/d and the main dietary sources were red wine (56%), 
strawberries (14%) and white wine (12%).
18
 Our group has also estimated the intake of 
resveratrol and piceid in the InCHIANTI (Invecchiare in Chianti, Aging in Chianti) 
study, a cohort of approximately 1,000 men and women, aged ≥ 65 years, and recruited 
in two small towns in the Tuscany (Italy).
19
 Dietary data was collected using a validated 
food frequency questionnaire every three years starting from 1998-2000. Phenol-
Explorer was also used to estimate the resveratrol and piceid intake. Mean (SD) intakes 
of resveratrol and piceid were 0.29 (0.38) and 0.76 (1.05) mg/d respectively 
(unpublished data). Again, red wine was the main food source, accounting for >90% of 
total resveratrol and piceid.  
To date, epidemiological studies assessing dietary resveratrol and piceid intake have 
shown similar results in Mediterranean countries since they usually have a high 
consumption of red wine, such as in France, Spain and Italy. However, in the Polish 
study, the mean intake was at least 9-fold lower than in Mediterranean. Further 
descriptive analyses are needed to estimate the intake of resveratrol and piceid in non-
Mediterranean countries, where greater variability in wine consumption, especially red 
wine, is found. 
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Resveratrol and piceid exposure assessment through biomarkers 
In modern nutritional epidemiology, there has been intense interest in the discovery, 
validation and use of nutritional biomarkers. They can be generally defined as a 
biochemical indicator of recent or long term dietary intake/nutritional status.
20
 The main 
advantage of using nutritional biomarker instead of dietary questionnaires is that they 
are objective and do not rely on biases or errors of subjects‟ responses. An „ideal‟ 
dietary biomarker would accurately reflect its dietary intake level and it would be 
specific, sensitive and applicable to many populations.
21
 The disadvantages of 
nutritional biomarkers are the necessity of biological samples, the complexity of the 
analytical methodology, and mostly, the high cost.
21
 Nutritional biomarkers can be 
classified into several types: recovery (e.g., doubly labeled water, urinary nitrogen and 
potassium), predictive (e.g., 24 h urinary sucrose and fructose), concentration and 
replacement biomarkers (e.g., vitamins, individual fatty acids, and phytoestrogens).
22
 
Despite the advantages of nutritional biomarkers compare to dietary surveys, few 
nutritional biomarkers have been validated so far.
22
 
In order to discover a biomarker of dietary resveratrol intake it is essential to have a 
comprehensive knowledge of resveratrol bioavailability and an analytical technique 
which allows resveratrol and resveratrol metabolites to be measured at low 
concentrations in biospecimens. 
Bioavailability of resveratrol 
Piceid, after hydrolysis of the sugar moiety, and resveratrol are usually absorbed in the 
small intestine. They are almost totally metabolized in the gut mucosa and the liver and 
conjugated to glucuronide and sulfate groups. Unabsorbed resveratrol reaches the colon 
and is converted to dihydroresveratrol by the microbiota. Then, it is absorbed, 
conjugated and found in the systemic circulation.
23, 24
 Finally, around 75% of these 
metabolites are excreted in urine and feces.
25
 Pharmacokinetics studies have shown that 
the maximum concentrations in urine of resveratrol and piceid metabolites are 30-60 
min and 6 h after dietary doses in humans, respectively.
26, 27
 Resveratrol and piceid 
standards are recovered in urine at similar percentages.
28
 At nutritional doses 
(<5mg/day), the absorption of resveratrol is higher than at pharmaceutical doses (from 
one hundred to thousands mg/day).
29
 
Methodology for assessment resveratrol in biospecimens 
A sensitive, precise, selective and robust analytical method is essential to measure 
resveratrol in biological samples. Instrumentation is usually gas or liquid 
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chromatography coupled to a single or a tandem mass spectrometer. Nowadays, an 
enzymatic or acidic hydrolysis is no longer performed, since we are interested in 
identifying and quantifying resveratrol metabolites (glucuronides and sulfates). Our 
group developed a method of characterizing the complete profile of resveratrol in urine 
using high performance liquid chromatography coupled to electrospray tandem mass 
spectrometry (LC-ESI-MS/MS) after a sample clean-up with solid-phase extraction 
(SPE).
30
 It was further improved to identify more resveratrol metabolites in a shorter 
chromatography run-time and was also adapted to 96-well SPE plates to allow a greater 
daily throughput.
31
 Using this methodology, we are able to identify 21 resveratrol 
derivatives, including resveratrol, dihydroresveratrol, piceid and their glucuronide- and 
sulfate-conjugated metabolites (Figure 1).
26
 Later two microbial metabolites, 3,4'-
dihydroxy-trans-stilbene and 3,4'-dihydroxybibenzyl dihydroresveratrol, have been 
reported using a similar method.
32 
Most analytical techniques used so far quantified resveratrol in biological samples only 
after an enzymatic hydrolysis,
33, 34
 and could not therefore measure the entire profile of 
resveratrol metabolites. Subsequent analytical methods were developed to measure the 
resveratrol metabolite profile in biospecimens, but after the intake of pharmaceutical 
doses and profiling fewer resveratrol metabolites.
27, 35
 
Validation studies of resveratrol biomarker 
There are several steps for validating a nutritional biomarker. The first one is to get an 
extensive knowledge of the bioavailability of resveratrol, especially the time- and dose-
response curves, after a single dose. This information is mostly provided by 
pharmacokinetic studies using resveratrol and resveratrol-rich foods (such as wine and 
grape juice). These studies have been reviewed previously.
8, 36
 
The second step is moving from acute to chronic studies. In a double-blind, placebo-
controlled study in 40 healthy men and women, after pharmacological doses of 
resveratrol (six-daily intake of resveratrol capsules [25, 50, 100 or 150 mg] at 4 h 
intervals) for 13 days, half-lives of plasma resveratrol were 1-3 and 2-5 hours following 
single-doses and repeated doses, respectively. Maximal plasma concentrations were 
almost directly proportional to resveratrol intake. High inter-individual variability and 
circadian variation were also observed.
37
 Another study administered capsules 
containing 0.5, 1, 2.5 or 5 g micronized resveratrol daily for 29 days to healthy men 
(n=22) and women (n=18) and identified resveratrol-3-O-sulfate, resveratrol-4‟- and 3-
O-glucuronide as the main plasma metabolites. Moreover, for micronized resveratrol 
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formulation, resveratrol with reduced particle size, maximal plasma levels of resveratrol 
and derived-metabolites were 3.6x higher than previously published values for standard 
resveratrol.
38, 39
 Our group has also carried out several randomized, crossover trials 
assessing the validity of urinary resveratrol metabolite profiles as a biomarker of dietary 
resveratrol after the consumption 3 different amounts of nutritional resveratrol doses via 
sparkling wine (300 mL/d, 0.36 mg/d resveratrol), white wine (200 mL/d, 0.40 mg/d 
resveratrol) and red wine (200 mL/d, 2.56 mg/d resveratrol) for 28 days in 10 healthy 
subjects. In these trials, the concentrations of total resveratrol metabolites increased 
upon increased resveratrol intake by 72.4 (95% confidence interval (CI), 48.5-96.2; 
P=0.005), 211.5 (95% CI, 166.6-256.3; P=0.005) and 560.5 (95% CI, 244.9-876.1; 
P=0.005) after consumption of sparkling, white, and red wine, respectively, while the 
concentration of these metabolites did not vary significantly after the washout and the 
control periods.
40
 
The third step is to correlate long-term dietary resveratrol intake using dietary 
questionnaires and resveratrol concentrations in biological samples in free living 
populations using large epidemiological studies. To the best of our knowledge, only two 
observational studies have assessed the usefulness of the resveratrol biomarker so far. In 
the PREDIMED study, a subsample of 1,000 men and women was evaluated, showing 
that concentrations of resveratrol metabolites in spot urine were highly correlated with 
dietary resveratrol intake (r=0.89; P < 0.001).
38 
The measurement of urinary resveratrol 
metabolites could discriminate wine consumers (resveratrol consumers) from non-wine 
consumers (sporadic or non-resveratrol consumers) with a sensitivity of 93.3% (95% 
CI, 91.5-94.7%) and a specificity of 92.1% (95% CI, 90.2-93.7%) using a cut-off of 
411.4 nmol/g creatinine.
41
 In the InCHIANTI study, 783 men and women, aged 65 
years and older, were included in the analysis and the correlation coefficient between 
dietary intake of resveratrol and total resveratrol metabolites in urine 24-h was 0.67 (P < 
0.001).
42
 
Combining all these studies, we can confirm that the sum of all urinary resveratrol 
metabolites is a valid concentration biomarker of total dietary resveratrol intake. 
However, further investigations are needed to assess the potential utility of plasma 
resveratrol concentrations as a biomarker of resveratrol intake in large observational 
studies. 
 
 
9 
 
Resveratrol and health effects: epidemiological evidence 
Although thousands of in vitro and in vivo animal studies
7
 and a few dozen intervention 
trials in humans
8
 evaluating the potential mechanisms and molecular targets of 
resveratrol action, few data come from large epidemiological studies. In this section, we 
review the available evidence concerning potential protection by resveratrol exposure, 
which can be estimated using dietary questionnaires and/or nutritional biomarkers, 
against mortality and chronic disease risk. 
Urinary resveratrol metabolite profiles and total dietary resveratrol intake were not 
associated with overall mortality after 9 years of follow-up in 783 community-dwelling 
men and women 65 years or older participating in the InCHIANTI study.
42
 However, in 
the PREDIMED study, high total resveratrol intake decreased 50% all-cause mortality 
in approximately 7,500 men and women at high cardiovascular risk after a mean follow-
up of 4.8 years.
43
 In this study, the dose-response effect was borderline significant, but 
the only significant results were observed with the highest quintile (>5.75mg/day), 
while in the InChianti study the resveratrol intake was lower and the results were 
presented in quartiles. 
Surprisingly, no association was observed between resveratrol intake and cardiovascular 
events (nonfatal acute myocardial infarction, nonfatal stroke or death from 
cardiovascular causes) in the same PREDIMED study.
44
 Similar null results were 
observed in the InCHIANTI study.
42
 Indeed in the InCHIANTI study, no association 
was observed between urinary resveratrol and inflammatory markers (CRP, IL-6, IL-1β, 
and TNF-α)42 that are well-known predictors of cardiovascular diseases.45, 46 Regarding 
other cardiovascular risk factors, total urinary resveratrol metabolites were inversely 
associated with glucose and triglyceride levels, and heart rate, but no association was 
observed with cholesterol levels and blood pressure in a subsample of 1,000 men and 
women in the PREDIMED study.
47
 However, in an Iranian cross-sectional study on 
2,618 adult men and women, metabolic syndrome, waist circumference, blood pressure, 
glucose, triglyceride and HDL levels were not related to dietary resveratrol intake; 
hypertension was even positively associated with resveratrol intake.
48
 Null results in 
this study could be due to very low intake of resveratrol (0.002mg/day) in this country. 
In China, a cross-sectional study in 1,393 men and women, aged from 35 to 75 years, 
dietary resveratrol intake from fruits, vegetables and nuts was not associated with 
cardiovascular factors (such as carotid intima–media thickness, blood pressure, and 
serum glucose and lipids).
49
 The main limitation of this Chinese study is that resveratrol 
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from wine and grape juice was not considered, which are by far the major food sources 
in wine consumer countries.
1
  
Few studies have looked for associations between resveratrol exposure and cancer risk 
In the InCHIANTI study, no association was observed between both urinary and dietary 
resveratrol and prevalent or incident overall cancer risk after 9 years of follow-up.
42
 In 
the SU.VI.MAX cohort, dietary resveratrol was not related to breast cancer risk in 
nearly 4,150 women with a median follow-up of 12.6 years.
50
 However, in the Swiss 
Canton of Vaud case control study, including 369 cases and 602 controls, breast cancer 
risk was inversely associated with dietary resveratrol from grapes but not from wine.
51
 
This could be explained because alcohol is a well-known risk factor for breast cancer,
52
 
and it may mask the effects of resveratrol. Furthermore, a study has evaluated the 
relationship between resveratrol intake and lung function in two large Dutch cohorts.
53
 
The Doetinchem (n=1,152) and Vlagtwedde-Vlaardingen (n=1,390) studies suggest an 
inverse association between dietary resveratrol and force vital capacity (FVC), but not 
with forced expiratory volume in 1 second (FEV1). Similarly, no significant association 
of resveratrol intake with the presence of airway obstruction, as present in chronic 
obstructive pulmonary disease, was found. 
In general, no associations were observed in most of the epidemiological studies so far, 
and it is possible that nutritional doses of resveratrol are too low to have the protective 
effects found at pharmacological doses (hundred milligrams to grams) in preclinical and 
clinical trials. Measurement error in the assessment of resveratrol exposure may also 
attenuate the results towards the null results. Furthermore, other compounds more 
abundant or with stronger effect may mask the effect of resveratrol, such alcohol, and 
other polyphenols. However, some protective effects against cardiovascular risk factors 
were suggested, such as the improvement of glucose and triglyceride levels and heart 
rate, although the evidence is still scarce. 
 
Conclusions 
Resveratrol is a fashionable bioactive compound that has been reported to exert a 
myriad of health benefits through many different mechanisms of action and molecular 
targets, mostly reported in vitro and in animal (preclinical) studies. In clinical trials, 
there is growing evidence that resveratrol could exert cardioprotective effects 
particularly through the improvement of inflammatory markers, atherogenic profile, 
glucose metabolism and endothelial function. However, a few epidemiological studies 
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have assessed the potential relationships between dietary resveratrol and the risk of 
cardiovascular and other chronic diseases. It is mainly due to the limitations for 
assessing properly dietary exposure of resveratrol. Phenol-Explorer is the first database 
containing food composition data on resveratrol and its derivatives. It will facilitate the 
estimation of resveratrol intake in large epidemiological settings. Moreover, the 
discovery and validation of a nutritional biomarker, urinary resveratrol, will allow 
resveratrol exposure to be objectively measured. The combination of dietary and urinary 
data on resveratrol will also improve the exposure estimations and, consequently, 
increase the strength of the findings.
54
  
Results from epidemiological studies are limited and still inconclusive, although some 
protective effects against cardiovascular diseases were suggested. Further studies are 
warranted to evaluate the associations with chronic diseases, taking into account current 
advances in the estimation of dietary resveratrol exposure. 
 
Acknowledgments 
The authors are grateful for the support granted by the Spanish government grants from 
Ministry of Economy and competitiveness (MINECO) and cofounded by FEDER 
(Fondo Europeo de Desarrollo Regional): the CONSOLIDER-INGENIO 2010 program, 
FUN-C-FOOD (CSD2007-063), and the JPI HDHL FOODBALL (PCIN-2014-133). 
We also thank the award of 2014SGR1566 from the Generalitat de Catalunya‟s Agency 
AGAUR. Partially funded by the International Nut and Dried Fruit Council Foundation 
(INC) in collaboration with the Bosch I Gimpera Foundation (FBG307906). M.U-S. 
thanks the „Ramón y Cajal‟ contract (RYC-2011-09677) from MINECO and Fondo 
Social Europeo. 
Conflicts of interest 
The authors declare no conflicts of interest.  
12 
 
References 
1. Zamora-Ros, R., et al. 2008. Concentrations of resveratrol and derivatives in 
foods and estimation of dietary intake in a Spanish population: European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. Br. J. 
Nutr. 100: 188-196. 
2. Chiva-Blanch, G., et al. 2011. Determination of resveratrol and piceid in beer 
matrices by solid-phase extraction and liquid chromatography-tandem mass 
spectrometry. J. Chromatogr. A. 1218: 698-705. 
3. Ragab, A. S., et al. 2006. Detection and quantitation of resveratrol in tomato 
fruit (Lycopersicon esculentum Mill.). J. Agric. Food. Chem. 54: 7175-7179. 
4. Hurst, W. J., et al. 2008. Survey of the trans-resveratrol and trans-piceid content 
of cocoa-containing and chocolate products. J. Agric. Food. Chem. 56: 8374-
8378. 
5. Farneti, B., et al. 2015. Is there room for improving the nutraceutical 
composition of apple? J. Agric. Food Chem. 63: 2750-2759. 
6. Renaud, S. & M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French 
paradox for coronary heart disease. Lancet. 339: 1523-1526. 
7. Baur, J. A. & D. A. Sinclair. 2006. Therapeutic potential of resveratrol: the in 
vivo evidence. Nat. Rev. Drug. Discov. 5: 493-506. 
8. Tome-Carneiro, J., et al. 2013. Resveratrol and clinical trials: the crossroad from 
in vitro studies to human evidence. Curr. Pharm. Des. 19: 6064-6093. 
9. Zamora-Ros, R., et al. 2012. Application of Dietary Phenolic Biomarkers in 
Epidemiology: Past, Present, and Future. J. Agric. Food. Chem. 60: 6648-6657. 
10. Shim, J.-S., et al. 2014. Dietary assessment methods in epidemiologic studies. 
Epidem. Health. 36: e2014009. 
11. Illner, A. K., et al. 2012. Review and evaluation of innovative technologies for 
measuring diet in nutritional epidemiology. Int. J. Epidemiol. 41: 1187-1203. 
12. Neveu, V., et al. 2010. Phenol-Explorer: an online comprehensive database on 
polyphenol contents in foods. Database (Oxford). 2010:bap024. 
13. Gonzalez-Barrio, R., et al. 2006. Comparison of ozone and UV-C treatments on 
the postharvest stilbenoid monomer, dimer, and trimer induction in var. 
'Superior' white table grapes. J. Agric. Food. Chem. 54: 4222-4228. 
14. Romero-Perez, A. I., et al. 2001. Method for the quantitative extraction of 
resveratrol and piceid isomers in grape berry skins. Effect of powdery mildew on 
the stilbene content. J. Agric. Food. Chem. 49: 210-215. 
15. Perez-Jimenez, J., et al. 2011. Dietary intake of 337 polyphenols in French 
adults. Am. J. Clin. Nutr. 93: 1220-1228. 
16. Tresserra-Rimbau, A., et al. 2013. Dietary intake and major food sources of 
polyphenols in a Spanish population at high cardiovascular risk: the PREDIMED 
study. Nutr. Metab. Cardiovasc. Dis. 23: 953-959. 
17. Gonzalez, S., et al. 2014. Dietary intake of polyphenols and major food sources 
in an institutionalised elderly population. J. Hum. Nutr. Diet. 27: 176-183. 
18. Grosso, G., et al. 2014. Estimated dietary intake and major food sources of 
polyphenols in the Polish arm of the HAPIEE study. Nutrition. 30: 1398-1403. 
19. Zamora-Ros, R., et al. 2011. Comparison of 24-h volume and creatinine-
corrected total urinary polyphenol as a biomarker of total dietary polyphenols in 
the Invecchiare InCHIANTI study. Anal. Chim. Acta. 704: 110-115. 
20. Potischman, N. & J. L. Freudenheim. 2003. Biomarkers of nutritional exposure 
and nutritional status: an overview. J. Nutr. 133 (Suppl. 3): 873S-874S. 
13 
 
21. Potischman, N. 2003. Biologic and methodologic issues for nutritional 
biomarkers. J. Nutr. 133 (Suppl. 3): 875S-880S. 
22. Jenab, M., et al. 2009. Biomarkers in nutritional epidemiology: applications, 
needs and new horizons. Hum. Genet. 125: 507-525. 
23. Nicholson, J. K., et al. 2012. Host-gut microbiota metabolic interactions. 
Science. 336: 1262-1267. 
24. Blaut, M. & T. Clavel. 2007. Metabolic diversity of the intestinal microbiota: 
implications for health and disease. J. Nutr. 137: 751S-755S. 
25. Wenzel, E. & V. Somoza. 2005. Metabolism and bioavailability of trans-
resveratrol. Mol. Nutr. Food. Res. 49: 472-481. 
26. Rotches-Ribalta, M., et al. 2012. Pharmacokinetics of resveratrol metabolic 
profile in healthy humans after moderate consumption of red wine and grape 
extract tablets. Pharmacol. Res. 66: 375-382. 
27. Walle, T., et al. 2004. High absorption but very low bioavailability of oral 
resveratrol in humans. Drug. Metab. Dispos. 32: 1377-1382. 
28. Burkon, A., Somoza, V. 2008. Quantification of free and protein-bound trans-
resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated 
diglucuronides-Two novel resveratrol metabolites in human plasma. Mol. Nutr. 
Food Res. 52:549–557. 
29. Meng, X., et al. 2004. Urinary and plasma levels of resveratrol and quercetin in 
humans, mice, and rats after ingestion of pure compounds and grape juice. J. 
Agric. Food Chem. 52:935–942. 
30. Urpi-Sarda, M., et al. 2005. Uptake of diet resveratrol into the human low-
density lipoprotein. Identification and quantification of resveratrol metabolites 
by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 
77: 3149-3155. 
31. Urpi-Sarda, M., et al. 2007. HPLC-tandem mass spectrometric method to 
characterize resveratrol metabolism in humans. Clin. Chem. 53: 292-299. 
32. Bode, L. M., et al. 2013. In vivo and in vitro metabolism of trans-resveratrol by 
human gut microbiota. Am. J. Clin. Nutr. 97: 295-309. 
33. Goldberg, D.M., et al. 2003. Absorption of three wine-related polyphenols in 
three different matrices by healthy subjects. Clin. Biochem. 36, 79-87. 
34. Ortuño, J., et al. 2010. Matrix effects on the availability of resveratrol in 
humans. Food Chem. 120, 1123-1130. 
35. Boockcok, D.J., et al. 2007. Phase I dose escalation pharmacokinetic study in 
healthy volunteers of resveratrol, a potential cancer chemopreventive agent. 
Cancer Epidemiol. Biomarkers Prev. 16:1246–52. 
36. Andres-Lacueva, C., et al. 2009. “Bioavailability and Metabolism of 
Resveratrol.” In Plant Phenolics and Human Health. Fraga, C. G., Ed.: 265-297. 
John Wiley & Sons, Inc. 
37. Almeida, L., et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol 
in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food. Res. 53 
(Suppl. 1): S7-15. 
38. Brown, V. A., et al. 2010. Repeat dose study of the cancer chemopreventive 
agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on 
the insulin-like growth factor axis. Cancer. Res. 70: 9003-9011. 
39. Howells, L.M., et al. 2011. Phase I randomized, double-blind pilot study of 
micronized resveratrol (SRT501) in patients with hepatic metastases-safety, 
pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila). 4:1419-
1425. 
14 
 
40. Zamora-Ros, R., et al. 2006. Diagnostic performance of urinary resveratrol 
metabolites as a biomarker of moderate wine consumption. Clin. Chem. 52: 
1373-1380. 
41. Zamora-Ros, R., et al. 2009. Resveratrol metabolites in urine as a biomarker of 
wine intake in free-living subjects: The PREDIMED Study. Free. Radic. Biol. 
Med. 46: 1562-1566. 
42. Semba, R. D., et al. 2014. Resveratrol levels and all-cause mortality in older 
community-dwelling adults. JAMA. Intern. Med. 174: 1077-1084. 
43. Tresserra-Rimbau, A., et al. 2014. Polyphenol intake and mortality risk: a re-
analysis of the PREDIMED trial. BMC. Med. 12: 77. 
44. Tresserra-Rimbau, A., et al. 2014. Inverse association between habitual 
polyphenol intake and incidence of cardiovascular events in the PREDIMED 
study. Nutr. Metab. Cardiovasc. Dis. 24: 639-647. 
45. Willerson, J. T. & P. M. Ridker. 2004. Inflammation as a cardiovascular risk 
factor. Circulation. 109: II2-10. 
46. Pearson, T. A., et al. 2003. Markers of inflammation and cardiovascular disease: 
application to clinical and public health practice: A statement for healthcare 
professionals from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation. 107: 499-511. 
47. Zamora-Ros, R., et al. 2012. High urinary levels of resveratrol metabolites are 
associated with a reduction in the prevalence of cardiovascular risk factors in 
high-risk patients. Pharmacol. Res. 65: 615-620. 
48. Sohrab, G., et al. 2013. Dietary polyphenols and metabolic syndrome among 
Iranian adults. Int. J. Food. Sci. Nutr. 64: 661-667. 
49. Li, G., et al. 2013. Estimated daily flavonoid and stilbene intake from fruits, 
vegetables, and nuts and associations with lipid profiles in Chinese adults. J. 
Acad. Nutr. Diet. 113: 786-794. 
50. Touvier, M., et al. 2013. Dual association between polyphenol intake and breast 
cancer risk according to alcohol consumption level: a prospective cohort study. 
Breast. Cancer. Res. Treat. 137: 225-236. 
51. Levi, F., et al. 2005. Resveratrol and breast cancer risk. Eur. J. Cancer. Prev. 14: 
139-142. 
52. Romieu, I., et al. Alcohol intake and breast cancer in the European Prospective 
Investigation into Cancer and Nutrition. Int. J. Cancer. In press. 
53. Siedlinski, M., et al. 2012. Dietary factors and lung function in the general 
population: wine and resveratrol intake. Eur. Respir. J. 39: 385-391. 
54. Freedman, L. S., et al. 2010. Can we use biomarkers in combination with self-
reports to strengthen the analysis of nutritional epidemiologic studies? 
Epidemiol. Perspect. Innov. 7: 2. 
15 
 
Figure legends: 
Figure 1. Chemical structures of resveratrol and its metabolites found in human 
biological samples. 
(A) Intestinal metabolism: trans- and cis-isomers. (B) Microbial metabolism. 
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Table 1. Food composition data sources for resveratrol and piceid content. Values are expressed as mg/100 g and total values per serving. 
Food item 
trans-
resveratrol 
cis-
resveratrol 
trans-
piceid 
cis-
piceid 
total resveratrol  
Reference 
mg/100g mg/100g mg/100g mg/100g mg/100g 
serving         
(g or mL) 
mg/serving 
Red wine 0.181 0.044 0.495 0.127 0.847 150 1.271 
1
 
Rosé wine 0.041 0.041 0.071 0.154 0.307 150 0.461 
1
 
White wine 0.010 0.016 0.260 0.022 0.074 150 0.111 
1
 
Sparkling wine 0.005 0.014 0.018 0.055 0.092 150 0.138 
1
 
Fortified wine 0.110 0.095 0.141 0.040 0.386 150 0.579 
1
 
Grape juice 0.010 tr 0.036 0.043 0.088 250 0.220 
1
 
Sangria 0.091 0.022 0.248 0.063 0.424 150 0.636 
1
 
Red grapes 0.250 tr 0.060 - 0.310 100 0.310 
1
 
White grapes 0.068 tr 0.025 - 0.093 100 0.093 
1
 
Peanut butter 0.065 - 0.014 - 0.080 30 0.024 
1
 
Peanuts, toasted 0.006 - - - 0.006 30 0.002 
1
 
Pistachios, toasted 0.007 - - - 0.007 30 0.002 
1
 
Berries, not specified
a
 0.008 - - - 0.008 50 0.004 
1
 
Tomatoes
b
 0.001 <0.001 <0.001 <0.001 0.001 100 0.001 
3 
Chocolate
c
 0.069 - 0.263 - 0.332 10-40 0.088 
4
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Beer 0.001 <0.001 <0.001 <0.001 0.001 330 0.005 
2
 
Itadori tea (infusion) 0.068 - 0.906 - 0.974 250 2.435 
1
 
Apple - - 0.030 0.010 0.040 250 0.100 
5 
Abbreviations: tr, traces. 
a
Berries included: blueberry, bilberry, sparkleberry, deerberry, cranberry, lingonberry and partridgeberry. 
b
Skin tomato values (5% of dry weight and 92% humidity) from MicroTom, breafsteak, UglyRipe, Heriloom and PlumTom varieties. 
c
Chocolate included: cocoa powder, unsweetened, semi-sweet, dark and milk chocolate, and chocolate syrup. Serving depends on chocolate 
product. 
